EyePoint, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
EYPT Nasdaq 2830 eyepoint.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for EyePoint, Inc.

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Feb 5th, 2026 5:00 am
Despite currently being unprofitable, EyePoint (NASDAQ:EYPT) has delivered a 195% return to shareholders over 3 years - Feb 2nd, 2026 3:45 am
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 16th, 2026 5:00 am
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 - Jan 7th, 2026 5:00 am
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains - Dec 23rd, 2025 12:06 pm
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know - Dec 22nd, 2025 10:00 am
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - Dec 22nd, 2025 6:10 am
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference - Dec 17th, 2025 5:00 am
EyePoint Pharmaceuticals (EYPT): Valuation Update Following Positive Phase 3 DURAVYU Safety Review - Nov 19th, 2025 5:17 pm
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration - Nov 19th, 2025 5:00 am
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Nov 9th, 2025 5:04 am
EyePoint Pharmaceuticals Inc (EYPT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... - Nov 7th, 2025 2:00 am
EyePoint Pharmaceuticals (EYPT): Forecast 61.3% Revenue Growth Tests Premium Valuation, Ongoing Losses - Nov 6th, 2025 2:17 pm
EyePoint (EYPT) Q3 2025 Earnings Call Transcript - Nov 5th, 2025 3:06 pm
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates - Nov 5th, 2025 6:15 am
EyePoint Pharmaceuticals: Q3 Earnings Snapshot - Nov 5th, 2025 5:22 am
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments - Nov 5th, 2025 5:00 am
EyePoint Announces Participation at Upcoming Investor Conferences - Nov 3rd, 2025 5:00 am
With 57% institutional ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is a favorite amongst the big guns - Oct 30th, 2025 4:17 am
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 - Oct 29th, 2025 5:00 am